Why Kura Oncology Stock Is Sliding Today
Shares of Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company, are down sharply in response to a clinical hold for the company's experimental leukemia treatment. The stock was down 15.6% as of 11:20 a.m. ET on Wednesday.
The Food and Drug Administration placed a partial clinical hold on a phase 1 trial with KO-539 after the death of a patient. The adverse event was potentially associated with differentiation syndrome (DS).
Image source: Getty Images.
Source Fool.com